science
Eli Lilly and Bayer Say German Policies Reduce Pharmaceutical Investment
Eli Lilly and Bayer stated that Germany's current approach to spending on innovative medicines could affect the country's appeal for future pharmaceutical projects. The companies linked their comments to existing reimbursement and pricing rules.
FI
thehindubusinessline.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly and Bayer said Germany's policies on spending for new medicines risk lowering the country's standing as a location for pharmaceutical investment. The companies pointed to current reimbursement and pricing arrangements as the main concern. They did not release specific figures on planned investment changes.
Bayer each issued statements through industry channels. The statements described the policies as a factor that could influence future site selection decisions. No timeline for any investment shift was provided in the statements.
Transparency
How sources framed this
FI
FI
Single source — no framing comparison available.
CorroborationModerate · 1 source
